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Abstract
Background: Severe iodine insufficiency in pregnancy has significant consequences, but there is inadequate
evidence to indicate what constitutes mild or moderate insufficiency, in terms of observed detrimental effects on
pregnancy or birth outcomes. A limited number of studies have examined iodine status and birth outcomes,
finding inconsistent evidence for specific outcomes.
Methods: Maternal iodine status was estimated from spot urine samples collected at 26–28 weeks’ gestation from
6971 mothers in the Born in Bradford birth cohort. Associations with outcomes were examined for both urinary
iodine concentration (UIC) and iodine-to-creatinine ratio (I:Cr). Outcomes assessed included customised birthweight
(primary outcome), birthweight, small for gestational age (SGA), low birthweight, head circumference and APGAR
score.
Results: There was a small positive association between I:Cr and birthweight in adjusted analyses. For a typical
participant, the predicted birthweight centile at the 25th percentile of I:Cr (59 μg/g) was 2.7 percentage points
lower than that at the 75th percentile of I:Cr (121 μg/g) (99% confidence interval (CI) 0.8 to 4.6), birthweight was
predicted to be 41 g lower (99% CI 13 to 69) and the predicted probability of SGA was 1.9 percentage points
higher (99% CI 0.0 to 3.7). There was no evidence of associations using UIC or other birth outcomes, including
stillbirth, preterm birth, ultrasound growth measures or congenital anomalies.
Conclusion: Lower maternal iodine status was associated with lower birthweight and greater probability of SGA.
Whilst small, the effect size for lower iodine on birthweight is comparable to environmental tobacco smoke
exposure. Iodine insufficiency is avoidable, and strategies to avoid deficiency in women of reproductive age should
be considered.
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Background
Iodine is essential for normal thyroid function and demands
for iodine increase during pregnancy to compensate for in-
creased renal clearance and to support normal foetal growth
and development [1, 2]. The consequences of severe mater-
nal iodine deficiency have long been known and include
goitre, stillbirth and severe neurological and growth impair-
ment in the offspring [1, 3]. However, less is known about
the more subtle consequences of mild or moderate defi-
ciency during pregnancy. The World Health Organization
(WHO) identifies insufficient iodine intake in pregnant pop-
ulations where the median urinary iodine concentration
(UIC) is less than 150 μg/L [3]. However, this threshold is
based on theoretical assumptions about absorption, meta-
bolic needs and excretion in urine [1] rather than observed
birth or pregnancy outcomes and is therefore limited in ap-
plication to pregnant populations.
To date, nine studies have examined maternal iodine status
and birth outcomes, with inconsistent findings reported be-
tween studies and for specific outcomes [4–12]. Three obser-
vational studies report that lower UIC is associated with
lower birthweight [4, 5, 7], higher risk of small for gestational
age (SGA) [4], shorter length at birth [5], smaller head cir-
cumference [5] and increased risk of preterm birth [7]. Lower
birthweight is an established risk factor for adult chronic dis-
ease [13]. However, the remaining six studies did not report
evidence of associations for major birth or pregnancy out-
comes [6, 8–12].
In countries without routine salt iodisation or fortification
programmes, there is a growing concern about possible en-
demic iodine insufficiency amongst women of reproductive
age [1, 14]. For example, of the 31 European countries that
assessed iodine intake in pregnancy, two thirds reported
inadequate intakes based on urinary iodine excretion
(< 150 μg/L) [14]. The current study, commissioned by the
Department of Health for England, directly addresses the
uncertainty surrounding the potential negative consequences
of low maternal iodine status for birth and pregnancy out-
comes. This research question is pertinent given that there is
no salt iodisation programme or pregnancy-specific recom-
mendations for iodine intake in the UK. We therefore hy-
pothesise that lower maternal iodine status is associated with
smaller foetal or birth size and poorer pregnancy outcomes.
Methods
Study design and participants
Women were recruited into the Born in Bradford (BiB)
cohort (n = 12,453) from 2007 to 2010 at 26 to 28 weeks’
gestation. The BiB cohort has been described in detail
elsewhere [15]. In brief, the cohort is multi-ethnic with
43% of participants in this study being of White Euro-
pean background and 43% being of Pakistani ethnic
background. A total of 7066 urine samples were pro-
vided by 6979 mothers (some women participated
during successive pregnancies), from which iodine status
was calculated. The large study size provides sufficient
power for detecting associations even of a potentially
modest size (see protocol at ClinicalTrials.gov
NCT03552341).
Assessment of urinary iodine and creatinine
Urine samples were collected at routine antenatal clinics
for oral glucose tolerance tests at 26 to 28 weeks’ gesta-
tion and therefore were all collected in the morning after
overnight fasting. Samples were stored at − 80 °C until
iodine and creatinine concentration analysis.
Urinary iodine(127) concentration (μg/L) was measured
at the University of Leeds using inductively coupled
plasma mass spectrometry (Thermo iCAP Q, Liverpool,
UK). The methodology and instrument were accredited
by the international EQUIP standardisation programme
[16]. Creatinine concentrations were evaluated using a
standard Jaffe reaction-based microplate assay. A series
of five quality control (QC) urines (along with a certified
reference material (CRM) (Seronorm trace elements
urine L-1)) were repeatedly analysed alongside partici-
pant samples to validate method accuracy. All QC and
CRM categories remained within expected or certified
ranges and displayed low variability.
For inter-laboratory comparison, a subset of BiB and
validation samples (3.8%, 271 of 6971) were provided at
regular intervals to the MRC Elsie Widdowson Labora-
tory in Cambridge. A high correlation was observed be-
tween UIC measurements across sites (r = 0.99). Full
laboratory analysis details and validation protocols are
provided in Additional file 1.
Birth and pregnancy outcomes
The primary outcome was standardised birthweight
(birthweight centile) calculated using UK customised
growth charts (Gestation-Related Optimal Weight
(GROW)) [17]. GROW calculations are valid and robust
[18] and are used as part of standard growth assessment
protocols in 81% of UK hospital trusts [19]. This ap-
proach calculates birthweight centile after considering
maternal height, weight, parity, ethnicity, child’s sex,
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gestation length and birthweight (see Additional file 1
for further details). The following secondary birth and
pregnancy outcomes were also examined: birthweight in
grams, low birthweight (< 2.5 kg), SGA (< 10th centile),
preterm birth (< 37 weeks), head circumference at birth,
stillbirth and APGAR score measured at 1 and 5min
after birth.
Intrauterine growth assessed via ultrasound
Foetal head circumference, biparietal diameter, femur
length, abdominal circumference and estimated weight
were measured via ultrasound scans amongst a sub-
sample of BiB participants at 33 to 34 weeks’ gestation.
Foetal weight was derived using the formula of Hadlock
[20]. Scans were not offered to women with twins or
known foetal abnormalities, and of 3805 women invited,
1859 scans were performed [21], with 1116 also provid-
ing urine samples.
Assessment of congenital anomalies
Congenital anomalies were identified up to age 5
through careful examination of linked medical record
data [22, 23]. Anomalies of metabolic origin (‘E70–90’
codes according to the 10th revision of the International
Classification of Diseases) and genetic or chromosomal
anomalies were excluded (details in Additional file 1).
Statistical analysis
Urinary iodine-to-creatinine ratio (I:Cr) (μg/g) was used
as the primary exposure to account for variation in urine
dilution [24], though all analyses were also conducted
using UIC. To avoid categorising iodine concentrations,
restricted cubic splines were fitted with four knots
placed at percentiles 5, 35, 65 and 95 and were used in
all multiple linear and logistic regression models. Robust
cluster (sandwich) estimates of variance were included
in all models to account for heteroscedasticity and sib-
ling clusters (successive pregnancies) [25].
Multiple imputation by chained equations, based on
100 imputed datasets, was used to correct for the effects
of incomplete covariate information [26] (details in Add-
itional file 1). Adjustment for confounding was informed
by directed acyclic graphs (see Additional file 1: Figure
S1). All models adjusted for maternal age, socioeco-
nomic and education category (see details in Add-
itional file 1: Table S1), ethnicity and season as potential
confounders. Covariates were omitted, as appropriate,
for modelling different outcomes (see Additional file 1:
Table S2). Additional adjustments, for potential compet-
ing exposures, included smoking in pregnancy, alcohol
in pregnancy, pregnancy complications (gestational dia-
betes, hypertension, preeclampsia), pre-pregnancy body
mass index (BMI), parity, child’s sex and length of gesta-
tion. To adjust for seasonality, pairs of sine and cosine
functions were prepared for each date across the year
[27]. Models that only included confounders were not
materially different from those additionally including
competing exposures, and therefore, all reported results
are from fully adjusted models.
Pre-specified sensitivity analyses (excluding iodine
supplement users or those with pregnancy complica-
tions) and subgroup analyses (ethnic background or so-
cioeconomic and education group) were undertaken for
all outcomes (details in Additional file 1), except for
binary outcomes where fewer than 100 cases were avail-
able. Additional sensitivity analyses were completed
using dietary data available in a sub-sample of the cohort
(see Additional file 1: Table S2). Figures present adjusted
predicted outcomes (continuous variables) or probabil-
ities (binary outcomes), across the range of iodine con-
centrations for an ‘average’ participant, i.e. primiparous,
White European, non-smoker, who did not report con-
suming alcohol or experience complications in preg-
nancy, employed and not materially deprived, of mean
gestation (39.6 weeks), age (27.2 years) and BMI (25.8 kg/
m2). Predicted outcomes at the 25th and 75th percen-
tiles of exposure were derived from these figures and
tabulated.
The overall contribution of iodine status to each out-
come was formally assessed with the Wald test. A two-
tailed p value < 0.01 was considered statistically signifi-
cant, and 99% confidence intervals (CIs) were used for
all comparisons. Stata version 15.1 (StataCorp) was used
for all analyses.
Results
Participant characteristics and iodine concentrations
In total, 12,453 women were recruited into BiB across
13,776 pregnancies; 6979 mothers (56%) provided a total
of 7066 urine samples at 26–28 weeks’ gestation, relating
to 7019 children, with some mothers participating dur-
ing more than one pregnancy. Samples were then ex-
cluded where no linkage to child records could be made,
for example, if the mother gave birth out of the area
(n = 47), samples from twins and triplets (n = 339) and
urine sample contamination or failed detection (n = 6).
Analyses therefore included data from 6674 urine sam-
ples provided by 6355 mothers. Samples from pregnan-
cies resulting in stillbirths (n = 37) were further excluded
from all analyses except where ultrasound measurements
or stillbirth was the outcome. A full overview of these
exclusions is given in Additional file 1: Figure S2.
The median (interquartile range (IQR)) I:Cr was
83.1 μg/g (59.4 to 121.2), and UIC was 76.2 μg/L (44.6
to 120.2). UIC was < 50 μg/L in 2042 (29%) women,
< 150 μg/L in 5925 (85%) women and exceeded
250 μg/L in just 236 (3%) women. For descriptive pur-
poses, the cohort was split into 3 categories according
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to I:Cr. Women who were most economically deprived
and less educated, those of Pakistani or other ethnic back-
ground, and those who used fewer supplements in preg-
nancy tended to have lower iodine levels (Table 1). In
unadjusted observations, the children of mothers in the
lowest I:Cr group tended to weigh less and were more
likely to be SGA than those whose mothers had higher
iodine concentrations (Table 2). In the lowest and highest
I:Cr groups, the mean (standard deviation (SD)) birth-
weight centile was 42.0 (28.5) vs. 45.2 (28.6) and birth-
weight was 3217 g (542) vs. 3271 g (535), respectively.
Pairwise correlations between the different growth mea-
sures are provided in Additional file 1: Table S3.
Birth and pregnancy outcomes
There was evidence of a positive association between I:
Cr and both birthweight centile and birthweight in
grams in adjusted analyses (Fig. 1a–c, Additional file 1:
Table S4). For a mother with typical characteristics (de-
fined above), the birthweight centile at the 25th percent-
ile of I:Cr (59 μg/g) was 2.7 percentage points lower than
that at the 75th percentile of I:Cr (121 μg/g) (99% CI 0.8
to 4.6, poverall 0.001). Similarly, predicted birthweight was
41 g lower at the 25th I:Cr percentile than at the 75th
(99% CI 13 to 69, poverall 0.001). The probability of SGA
was also 1.9 percentage points higher (99% CI 0.0 to 3.7,
poverall 0.010). However, there was no evidence of an as-
sociation for low birthweight (< 2.5 kg) (Fig. 1d, Add-
itional file 1: Table S4). Apparent thresholds in the
association between I:Cr and birthweight centile, birth-
weight in grams and SGA around 150 μg/g (Fig. 1)
should be interpreted with caution given the small pro-
portion of participants with I:Cr measurements above
this level (15%), with associated wide CIs and inconsist-
ency of thresholds in sensitivity analyses (below).
There was no evidence of any association between I:Cr
and ultrasound measurements at 34 weeks’ gestation,
head circumference at birth or APGAR score measured
at 1 or 5 min after birth. Similarly, the probability of
stillbirth, preterm birth or congenital anomalies was also
not associated with maternal iodine concentration (Fig. 2,
Additional file 1: Figure S3 & Table S4). There was no
evidence of an association between UIC and the out-
comes examined (Additional file 1: Table S4).
Subgroup and sensitivity analyses
There was no evidence of effect modification (inter-
action) by ethnic background (White European vs. Paki-
stani) in the association between I:Cr and any outcome
(size at birth, intrauterine size, APGAR score, preterm
or congenital anomalies). For the comparison between
socioeconomic and education categories (more deprived
and less educated vs. less deprived and more educated),
there was only evidence of effect modification in the
association between I:Cr and birthweight centile (p =
0.008) and head circumference at birth (p = 0.007) (Add-
itional file 1: Figure S5 & S10, panel g-h). In the more
deprived and less educated women, there was a stronger
tendency for higher birthweight centile with higher I:Cr
across the range of usual intakes (note frequency histo-
grams). Differences in association patterns were less ob-
vious for head circumference.
Estimates from a sensitivity analysis using only women
with complete data were not substantively different from
primary analyses using imputed data (Additional file 1:
Figure S5-S14, panel a). For all outcomes, sensitivity ana-
lyses (excluding outliers, those with complications in
pregnancy or iodine supplement users) were not materi-
ally different from the full cohort analyses (Add-
itional file 1: Figure S5-S14, panel b-d). Apparent
thresholds in the association between I:Cr and birth-
weight centile, SGA and birthweight in grams, around
150 μg/g (Fig. 1) were no longer present after excluding
a small number of I:Cr outliers (n = 39) (Additional file 1:
Figure S5-S7, panel b), with trends remaining similar
across the range of I:Cr values where more data were
available. There was no evidence of any association after
additionally adjusting for diet in pregnancy (data avail-
able for approximately one third of participants). Results
for congenital anomalies were not different after exclud-
ing consanguineous relationships.
Discussion
In the largest study of its type to date, and in a preg-
nant population characterised as having insufficient
iodine intake according to WHO-outlined thresholds
(UIC < 150 μg/L), evidence was found to support a
small association between lower I:Cr measured at 26–
28 weeks’ gestation and lower birthweight centile, birth-
weight in grams and higher probability of SGA. In ab-
solute terms, between the 25th and 75th I:Cr percentile
(59 and 121 μg/g), birthweight centile was estimated to
be 2.7% higher, birthweight was 41 g higher and the
probability of being SGA was 1.9% lower, for a typical
participant in this cohort. The estimated birthweight
difference of 41 g is small but of comparable size to the
birthweight differences observed with environmental
tobacco smoke exposure in pregnancy [28]. There was
no evidence to support associations between I:Cr and
all other outcomes examined, including measures of
intrauterine growth from ultrasound scans at 34 weeks’
gestation, head circumference at birth, APGAR score,
low birthweight, stillbirth, preterm birth and congenital
anomalies. Additionally, UIC was not found to be asso-
ciated with any outcomes.
Amongst comparable studies, this is the largest to
date, with the next largest study including 3140 pregnan-
cies [11]. Our findings for birthweight are concordant
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Table 1 Maternal characteristics according to urinary iodine-to-creatinine ratio
All participants,
n = 6637
Iodine-to-creatinine ratio (sample split into thirds)
Lower third (< 67 μg/g),
n = 2213
Middle third (67 to 105 μg/g),
n = 2212
Higher third (> 105 μg/g),
n = 2212
I:Cr (μg/g), geometric mean (99% CI) 86.0 (84.5 to 87.5) 48.5 (47.8 to 49.3) 83.4 (82.8 to 84.0) 157.2 (154.3 to 160.2)
I:Cr (μg/g), median (IQR) 83.1 (59.4 to 121.2) 51.4 (42.7 to 59.4) 83.2 (74.4 to 93.3) 146.1 (121.2 to 185.2)
UIC (μg/L), geometric mean (99% CI) 70.8 (69.1 to 72.5) 45.9 (44.2 to 47.8) 70.0 (67.6 to 72.6) 110.4 (106.4 to 114.5)
UIC (μg/L), median (IQR) 76.2 (44.6 to 120.2) 52.2 (29.1 to 78.0) 77.4 (47.3 to 112.5) 117.6 (71.8 to 178.8)
Age (years), mean (SD) 27.2 (5.6) 26.5 (5.5) 27.3 (5.6) 27.8 (5.6)
BMI (kg/m2), mean (SD) 25.8 (5.5) 26.5 (5.8) 25.9 (5.4) 25.1 (5.1)
Socioeconomic status†
Least deprived and most
educated
1241 (21) 307 (16) 429 (22) 505 (25)
Employed, not materially deprived 1231 (21) 335 (17) 440 (22) 456 (23)
Employed, no access to money 917 (16) 320 (16) 295 (15) 302 (15)
Receives benefits, not materially
deprived
1594 (27) 633 (32) 505 (26) 456 (23)
Most economically deprived 920 (16) 360 (18) 293 (15) 267 (13)
Ethnic background, n (%)
White British and European 2877 (44) 800 (36) 1016 (46) 1061 (48)
Pakistani 2827 (43) 1064 (48) 914 (42) 849 (39)
Others (Black, Indian, mixed,
others)
901 (14) 337 (15) 271 (12) 293 (13)
Parity
0 2931 (44) 933 (42) 966 (44) 1032 (47)
1 1859 (28) 600 (27) 623 (28) 636 (29)
2 1059 (16) 371 (17) 361 (16) 327 (15)
3+ 788 (12) 309 (14) 262 (12) 217 (10)
Health and lifestyle in pregnancy
Gestational diabetes, n (%) 499 (8) 152 (7) 167 (8) 180 (8)
Pre-pregnancy hypertension,
n (%)
50 (0.8) 21 (1.0) 17 (0.8) 12 (0.5)
Pregnancy-induced hypertension,
n (%)
375 (6) 125 (6) 126 (6) 124 (6)
Preeclampsia, n (%) 173 (3) 61 (3) 55 (2) 57 (3)
Drank any alcohol, n (%) 958 (14) 299 (14) 335 (15) 324 (15)
Smoked, n (%) 969 (15) 302 (14) 352 (16) 315 (14)
Used any supplements, n (%) 1334 (20) 213 (10) 382 (17) 739 (33)
Iodine-containing supplements,
n (%)
988 (15) 123 (6) 264 (12) 601 (27)
White fish intake* (g/day), mean
(SD)
21.0 (27.0) 18.7 (26.3) 22.1 (28.2) 22.1 (26.1)
Oily fish intake* (g/day), mean
(SD)
1.4 (3.8) 1.0 (3.2) 1.5 (4.2) 1.7 (4.0)
Total fish intake* (g/day), mean
(SD)
23.8 (29.3) 20.8 (28.3) 25.1 (30.7) 25.4 (28.8)
Eat 5 fruits/vegetables per day*,
n (%)
Always 422 (19) 122 (16) 160 (21) 140 (19)
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with three prior studies reporting associations of lower
birthweight with lower iodine status [4, 5, 7]. However,
in each case, the association was only examined with
UIC, but UIC was not associated with any outcomes in
this study. Six other studies also report no evidence of
associations between birthweight and UIC [6, 8–12] or I:
Cr [11, 12]. The higher probability of SGA with lower I:
Cr observed here also supports observations from one
prior study [4], but not five others reporting no evidence
of associations [6, 7, 10–12]. Inconsistency between
studies and within specific outcomes may be attributed
to differences in the time period of assessment, with iod-
ine status during key developmental stages potentially
having differential effects on foetal growth. Furthermore,
only three prior studies corrected for urinary dilution
using creatinine concentration in urine. The absence of
associations across all birth or pregnancy outcomes in
this study may reflect measurement error in some out-
come assessments such as for intrauterine growth. Alter-
natively, iodine status at 26–28 weeks’ gestation may be
outside of critically important time windows for some
aspects of development, or iodine status may not be re-
sponsible for the effects on these birth or pregnancy
outcomes.
In this study, a sampling point of 26–28 weeks was se-
lected to ensure iodine exposure assessment was
Table 1 Maternal characteristics according to urinary iodine-to-creatinine ratio (Continued)
All participants,
n = 6637
Iodine-to-creatinine ratio (sample split into thirds)
Lower third (< 67 μg/g),
n = 2213
Middle third (67 to 105 μg/g),
n = 2212
Higher third (> 105 μg/g),
n = 2212
Sometimes 1700 (75) 601 (77) 558 (72) 541 (75)
Never 151 (7) 57 (7) 52 (7) 42 (6)
BMI body mass index, CI confidence intervals, I:Cr urinary iodine-to-creatinine ratio, IQR interquartile range, SD standard deviation, UIC urinary iodine concentration
*Data from women who were asked about diet in pregnancy (n = 2776)
†Refer to supplement table S1 for details
Table 2 Pregnancy and birth outcomes for all participants and according to maternal iodine-to-creatinine ratio
Iodine-to-creatinine ratio (cohort split into thirds)
All participants,
n = 6637
Lower third (< 67 μg/g),
n = 2213
Middle third (67 to 105 μg/g),
n = 2212
Higher third (> 105 μg/g),
n = 2212
Size at birth
Birthweight centile, mean (SD) 43.6 (28.5) 42.0 (28.1) 43.7 (28.9) 45.2 (28.6)
Birthweight (g), mean (SD) 3245 (549) 3217 (542) 3247 (568) 3271 (535)
Small for gestational age (< 10th
centile), n (%)
880 (13) 311 (14) 298 (13) 271 (12)
Low birthweight (< 2.5 kg), n (%) 466 (7) 167 (8) 161 (7) 138 (6)
Head circumference at birth (mm),
mean (SD)
343 (16) 343 (15) 343 (17) 344 (15)
APGAR score (out of 10), median (IQR)
1 min 8.5 (1.4) 8.5 (1.3) 8.4 (1.4) 8.5 (1.1)
5 min 9.0 (0.7) 9.0 (0.7) 9.0 (0.7) 9.1 (0.7)
Ultrasound scan (34 weeks) estimations, mean (SD)
Head circumference (mm) 315 (9) 314 (9) 315 (9) 315 (9)
Biparietal diameter (mm) 8.5 (0.3) 8.5 (0.3) 8.5 (0.3) 8.5 (0.3)
Femur length (mm) 65 (2) 65 (2) 65 (2) 65 (2)
Abdominal circumference (mm) 295 (14) 294 (14) 295 (14) 296 (14)
Estimated weight (g) 2237 (237) 2228 (244) 2234 (228) 2248 (240)
Preterm (< 37 weeks), n (%) 354 (5) 114 (5) 134 (6) 106 (5)
Stillbirth, n (%) 37 (0.6) 12 (0.5) 14 (0.6) 11 (0.5)
Congenital anomalies, n (%)
All 353 (5.3) 123 (5.6) 127 (5.7) 103 (4.7)
Nervous system 125 (1.9) 39 (1.8) 44 (2.0) 42 (1.9)
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conducted before the ultrasound outcomes measured at
around 34 weeks. Foetal iodine demands are known to
increase throughout pregnancy [29], with demands peak-
ing during the second half of pregnancy [30]. However,
despite this increase in demand, iodine excretion has
been demonstrated to remain somewhat constant
throughout the pregnancy in other populations present-
ing mild iodine deficiency [31, 32]. Our time point
therefore likely represents a snapshot of a pregnant
population during a period of peak thyroid stress and of
stable iodine excretion.
According to the WHO-outlined threshold [3], preg-
nant populations with sufficient iodine have a median
UIC > 150 μg/L, but the median UIC in this study was
just 76 μg/L. Whilst observing a wide range of iodine
concentrations in the BiB cohort, median UIC was the
lowest of all previous studies [4–12]. The difference po-
tentially positions this work to better quantify associa-
tions in lower sufficiency settings. Higher concentrations
in some settings may explain why several previous stud-
ies did not report associations for key growth outcomes,
as any effect of iodine is likely to be dose-dependent.
The effect sizes reported here are dependent on the iod-
ine distribution in the BiB study population, and replica-
tion is therefore warranted in other settings.
In the UK, where salt iodisation or supplementation
for iodine is not routine, iodine is primarily sourced
from only a few foods (largely from milk but also from
some fish, meat and cereals) [33]. Women who avoid
dairy or are vegetarian and who do not use supplements
may therefore be at greater risk of insufficiency, particu-
larly during pregnancy when iodine demands rise, and
consequently may be at greater risk of having lower-
weight babies. Lower weight at birth is a well-established
risk factor for chronic disease in later life [13, 34]. Fur-
thermore, some women may be at greater risk of having
low iodine status: the UK Low Income National Diet
and Nutrition Survey reported that Black or Asian
Fig. 1 Estimated birth size for children of typical mothers, across the range of maternal I:Cr concentrations. Histograms illustrate the distribution
of iodine concentrations, and although the figures are curtailed at 300 μg/g, the splines (solid line) and 99% CIs (dashed lines) were drawn using
data from all participants. Splines were drawn after adjustment for confounders (details in Supplemental table S1). The spline position in these
figures illustrates the predicted estimate for typical participants (primiparous; White ethnic background; ‘employed and not materially deprived’;
did not smoke, drink or experience complications in pregnancy; and have average BMI, age and gestation length)
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women were more likely to be below the UK’s lower ref-
erence nutrient intake than White women [35]. The pre-
dicted estimates in this study may also be amplified
amongst those with several risk factors for smaller-
birthweight babies. The majority of women of repro-
ductive age are likely unaware of their iodine status or
good dietary sources, as only 23% of women who were
pregnant or of reproductive age in the UK had heard of
iodine, compared to 100% for folic acid [36]. Given the
presence of these at-risk groups, and evidence of a con-
tinuing decrease in iodine consumption amongst UK
women of childbearing age [35], our finding of an asso-
ciation between lower iodine status and increased risk of
lower birthweight is highly relevant for the UK
population.
There was evidence of different associations between I:
Cr and birthweight centile in women according to
deprivation and education category, with more apparent
associations in those who were ‘more deprived and less
educated’. These differences may result from residual
confounding or could indicate better resilience or some
compensatory mechanisms amongst more affluent and
Fig. 2 Estimated intrauterine size and pregnancy outcomes for typical mothers, across the range of maternal I:Cr concentrations. Histograms
illustrate the distribution of iodine concentrations, and although the figures are curtailed at 300 μg/g, the splines (solid line) and 99% CIs (dashed
lines) were drawn using data from all participants. Splines were drawn after adjustment for confounders (details in Supplemental table S1). The
spline position in these figures illustrates the predicted estimate for typical participants (primiparous; White ethnic background; ‘employed and
not materially deprived’; did not smoke, drink or experience complications in pregnancy; and have average BMI, age and gestation length)
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educated women, possibly driven by generally better
general health or dietary status, and thus, women who
are ‘less educated and more deprived’ may be at greater
risk of potential negative effects of lower iodine status in
pregnancy.
Severe iodine deficiency results in a range of disorders
in offspring, including mental deficiency and short stat-
ure [3]. Iodine plays an essential role in thyroid-
mediated foetal growth and development [2], but there
is little evidence to indicate an optimum iodine concen-
tration or a threshold associated with better pregnancy
or birth outcomes. Within the range of comparatively
low iodine concentrations observed in this study, evi-
dence for a threshold or plateau in associations was
weak.
Study strengths include the large study size and power
to detect potential differences in associations. Data are
from a well-characterised and multi-ethnic cohort with a
comprehensive range of objective outcomes, allowing for
evaluation of potential associations with different aspects
of growth and development in utero and at birth. A
more accurate measure of iodine status in pregnant
women was achieved by accounting for urine dilution
variability using I:Cr [37]. Spot urine samples are consid-
ered a reliable marker of population iodine status by the
WHO [3], and all samples used here were collected after
overnight fasting and at a similar time of day. The robust
and validated urine sample analysis, including participa-
tion in the international EQUIP programme [16], is a
strength in this work. The use of standardised birth-
weights, calculated using nationally representative data-
sets, is also a strength, along with data-driven
exploration of potential associations and threshold ef-
fects, rather than the arbitrary categorisation of iodine
concentration. Participants were drawn from one geo-
graphic region but covered a wide range of social back-
grounds and different ethnicities. However, in sensitivity
analyses, our results are consistent across various sub-
groups suggesting generalizability.
Despite carefully controlling for potential confounders,
there remains the chance that observed associations re-
sult from residual confounding in unmeasured or in-
accurately characterised variables. The single assessment
of urinary iodine also limits the exploration of changes
through pregnancy and any possible effects on stages of
foetal development. Random measurement error in esti-
mating iodine status from single spot urine samples may
also limit analyses; however, this would bias estimates
towards the null [38] and may only explain why associa-
tions were not seen for other outcomes.
It remains challenging to establish whether the ab-
sence of associations in some other studies resulted from
measurement error, assessment during less critically im-
portant time periods in pregnancy or the fact that other
populations had higher median UIC and may therefore
have been less likely to observe associations. Further
studies in populations without routine fortification pro-
grammes or with relatively low status or that evaluate
birth outcomes in relation to iodine status throughout
pregnancy (or prior to pregnancy) may provide clarity
on these issues. Research into alternative biomarkers will
also help to improve characterisation of usual or changes
in maternal iodine status.
Conclusions
Many countries lack pregnancy-specific recommenda-
tions relating to iodine intake or iodine status, owing to
the absence of strong or consistent evidence, at least
amongst those without severe deficiency. Given our find-
ing of an association between lower iodine status and
lower birthweight, along with the low status of women
of reproductive age in this and other countries in Europe
[12, 39], this knowledge gap should be addressed as a
priority, particularly as lower birthweight has been
linked to increased incidence of diabetes [40], risk of
leukaemia [41] and all-cause adult mortality [13, 34].
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